Systemic lupus erythematosus (SLE), a disorder of the immune system, is potentially curable by allogeneic bone marrow transplantation (alloBMT). Until recently, alloBMT was limited by donor availability and toxicity. Reduced intensity conditioning (RIC) combined with posttransplantation cyclophosphamide (PTCy) has improved the availability and safety of alloBMT permitting its exploration in severe-refractory autoimmune illnesses. We report the six-year follow-up of a young female whose refractory SLE-associated nephrosis resolved after RIC alloBMT with PTCy. Lupus (2017) 26, 773-776.
Allogeneic bone marrow transplantation (alloBMT), by eradicating donor hematopoiesis, can extinguish autoreactive lymphocytes. AlloBMT is currently utilized to treat inborn errors of metabolism, bone marrow failure, hemoglobinopathies and hematologic malignancies. Its use in other illness has been limited by preparative regimen toxicity, donor availability, poor engraftment and late transplant toxicities such as graft-versus-host-disease (GVHD). However, reduced intensity conditioning (RIC) in combination with use of alternative donors has expanded the safety and access to alloBMT. 1 Importantly, post-transplantation cyclophosphamide (PTCy) [2] [3] [4] has reduced the rate of GVHD from related haploidentical donors to that seen with matched donors. [5] [6] [7] This improved access and safety of alloBMT may permit its use to treat severe-refractory autoimmune illnesses. Here, we present the long-term follow-up of a patient with refractory systemic lupus erythematosus (SLE) who six years ago received a RIC alloBMT with PTCy, primarily for sickle cell anemia.
In the summer of 2003, an 18-year-old female of Nigerian descent was diagnosed with systemic lupus based on antinuclear antibodies, anti-Smith antibodies, a low complement component 3 and polyarthritis. Her past medical history was significant for sickle cell anemia. Her initial SLE treatment was prednisone and high-dose mycophenolate mofetil. Despite this intervention, within six months she developed focal proliferative and membranous lupus nephritis with nephrotic range proteinuria.
Concurrently, she suffered an anticardiolipin IgG antibody mediated renal vein thrombosis and anticoagulation was initiated. Her renal disease would eventually prove to be refractory to tacrolimus; pulse cyclophosphamide was introduced. After 11 cyclophosphamide infusions (October 2004 through August 2006), rituximab was initiated in September of 2006 as a remittive agent. However, intense rituximab infusion reactions required its discontinuation just after two infusions; she continued to receive an additional three quarterly-infusions of cyclophosphamide (completed June 2007). While the nephrosis improved on therapy, her steroid dose could not be tapered below 7.5 mg daily. Her SLEDAI score before alloBMT was calculated at six.
Her hemoglobin SS induced vaso-occlusive and bone pain crises. The early years of her disease were mild with two to three pain crises per year, managed mostly at home. However, since the diagnosis of SLE, her sickle cell disease had become more complicated. In late 2004, her hemoglobin F quantification was 10% (>30% protects the cell from sickling) and Hgb S 83%. During the year prior to alloBMT, she suffered pain crises once every one to two months, many of which required hospitalization and red cell transfusion support. Before alloBMT, controlling her sickle cell pain required 120 mg of extended-release morphine daily plus breakthrough opiate use.
At 25 years of age, she underwent a RIC, haploidentical, CMVþ allogeneic bone marrow transplant from her brother with sickle cell trait (Hgb: ASA2). Her preparative conditioning regimen was fludarabine (day À6 through day À2), cyclophosphamide (day À6, day À5), antithymocyte globulin (day À4, day À3) and 200cGY total body irradiation (day À1). On day 0 (17 September 2010), she underwent a red cell exchange transfusion followed by infusion of her brother's hematopoietic stem cells. For GVHD prophylaxis, she received PTCy (day þ3, day þ4), mycophenolate mofetil and tacrolimus (both starting day þ5). Her baseline 7.5 mg of daily prednisone was maintained. Her course was complicated by tacrolimus induced posterior reversible enceophalopathy syndrome (PRES) and CMV virema. Both were medically managed without long-term sequel. She attained neutrophil recovery on day þ17 and full donor whole blood and T-cell engraftment by day þ28. Mycophenolate mofetil and sirolimus (substituted for tacrolimus secondary to PRES) were discontinued on day þ35 and day þ360, respectively. She never developed acute nor chronic GVHD and remains with full T-cell engraftment.
Nine months after alloBMT, her anticoagulation therapy was stopped and her opiate requirements began to wane. By 14 months, continuous opiate use ended. In the immediate post-transplant period her protein to creatinine ratio increased and plaquinil 200 mg twice daily was initiated on day þ76. A prednisone tapered was initiated at 21 months and completed 2.5 years after alloBMT. She had normalization of her urine protein 2.7 years after alloBMT. Her medical course was further complicated by bilateral septic necrosis of her humeri requiring bilateral humeral head core decompression (1.6 years and 2.4 years), cryptogenic, marked-pitting lower extremity lymphedema responsive to local measures (2.6 years -ongoing), cholelithiasis requiring a cholecystectomy (3.6 years), grade I/II thrombocytopenia (3.9 yearsongoing) and transient pityriasis rosea (4.3 years). She is currently 5.5 years post alloBMT, she retains full engraftment, her remittive therapy is limited to plaquinil 200 mg twice daily and her current AlloBMT Figure 1 Urine protein:creatinine ratio over time.
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SLEDAI score is three, secondary to a low complement level and moderate thrombocytopenia. Her urine protein to creatinine ratio normalized at 15 months (Figure 1 ). At 30 years of age, she has regular monthly menses and wishes to conceive. The combination of RIC and PTCy has markedly expanded access and lowered the morbidity and mortality of alloBMT. After RIC, engraftment is not synonymous with neutrophil recovery. Accordingly, peripheral blood donor-patient chimerism analysis determines graft status. 8 Additionally, long-term graft survival does not occur when donor cells are lost within the T-cell compartment. 9, 10 In the malignant setting, RIC with PTCy is associated with a >90% T-cell engraftment. However, lower engraftment rates are encountered with alloBMT for non-malignant conditions, especially with RIC. 11, 12 This patient underwent alloBMT for two nonmalignant conditions: sickle cell anemia and SLE. AlloBMT is an established therapy for hemoglobinopathies. However, alloBMT for autoimmune illnesses is novel. We and others have established a role in high dose chemotherapy with and without stem cell rescue for severe refractory autoimmune illnesses. [13] [14] [15] [16] And, while high dose chemotherapy improves quality of life, most patients relapse within five years. AlloBMT holds the promise of disease eradication. As compared to patients with hemoglobinopathies, full donor chimerism with RIC may be easier to achieve in refractory SLE patients given their previous immunosuppressive therapies. The morbidity and mortality of RIC with PTCy is low and, since PTCy expands the donor pool, the majority of refractory lupus patients would potentially be eligible for such a transplant. The transient CMV viremia experienced by this patient is commonly encountered during alloBMT. Since her alloBMT, both illnesses are well controlled. In terms of her SLE: she has stopped all immunosuppression except plaquinil and her urine protein to creatinine ratio, which was once as high as 5.27, has normalized. Given the experience of this index patient, the role of alloBMT in the treatment of refractory autoimmune illnesses deserves exploration.
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